Conclusions: One-year treatment with a non-calcium-containing phosphate binder may hamper the progression of cardiac valve calcification and slow the decline of renal function, as well as reduce serum concentration of FGF-23 and CRP and urinary phosphorus excretion.
PMID: 23807650 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)